Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 9:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 11,191 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Hemangioma
Interventions
abdominal ultrasound, Dermatologic Examination
Procedure · Other
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
Up to 6 Months
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Kansas City, Missouri
Conditions
Acute Coronary Syndrome, Myocardial Infarction
Interventions
Elecsys® Troponin T hs Gen 6, Blood sample collection
Diagnostic Test · Procedure
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
20 Years and older
Enrollment
5,429 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
26
States / cities
El Centro, California • La Jolla, California • Gainesville, Florida + 21 more
Completed No phase listed Observational

SHARE Approach Evaluation

NCT06062940
Conditions
Shared Decision Making
Interventions
SHARE Approach
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 89 Years
Enrollment
176 participants
Timeline
2019 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Catecholaminergic Polymorphic Ventricular Tachycardia
Interventions
SGT-501
Drug
Lead sponsor
Solid Biosciences Inc.
Industry
Eligibility
7 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
4
States / cities
Boston, Massachusetts • Rochester, Minnesota • Cleveland, Ohio + 1 more
Completed Not applicable Interventional

ADAPT: Approach to Dance for Autism

NCT07216768
Conditions
Autism Spectrum Disorder (ASD)
Interventions
Ballet Class
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
6 Years to 12 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
New York, New York
Conditions
Cervical Cancer
Interventions
M7824, Carboplatin, Paclitaxel, Bevacizumab, Cisplatin, Radiotherapy
Drug · Radiation
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
Stanford, California • Augusta, Georgia • Henderson, Nevada + 2 more
Conditions
Glioblastoma
Interventions
Ibrutinib, Radiation, Temozolomide (TMZ)
Drug · Radiation
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Bladder Adenocarcinoma, Bladder Mixed Adenocarcinoma, Bladder Squamous Cell Carcinoma, Bladder Urothelial Carcinoma, Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant, Infiltrating Bladder Urothelial Carcinoma With Giant Cells, Infiltrating Bladder Urothelial Carcinoma With Glandular Differentiation, Infiltrating Bladder Urothelial Carcinoma With Trophoblastic Differentiation, Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant, Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant, Infiltrating Bladder Urothelial Carcinoma, Nested Variant, Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant
Interventions
Carboplatin, Cisplatin, Cystectomy, Doxorubicin, Durvalumab, Gemcitabine, Methotrexate, Vinblastine
Drug · Procedure · Biological
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Palo Alto, California
Conditions
Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
trastuzumab, Pertuzumab, docetaxel, carboplatin, doxorubicin, cyclophosphamide, paclitaxel, Bevacizumab
Biological · Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Advanced Malignancies
Interventions
INCA32459-101
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Los Angeles, California • Houston, Texas
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Characterization of Clinical Skeletal and Cardiac Impairment in Carriers of DMD and BMD

NCT02972580
Conditions
Duchenne Muscular Dystrophy, Becker Muscular Dystrophy
Interventions
Genetic characterization
Genetic
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2030
U.S. locations
1
States / cities
Columbus, Ohio
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Cascade Testing in Families With Newly Diagnosed Hereditary Breast and Ovarian Cancer Syndrome

NCT04009148
Conditions
BRCA-Mutated Ovarian Carcinoma, BRIP1 Gene Mutation, MSH2 A636P, MLH1 Gene Mutation, MSH6 Gene Mutation, PMS2 Gene Mutation, EPCAM, RAD51C Gene Mutation
Interventions
CASCADE genetic screening
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 99 Years
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2027
U.S. locations
1
States / cities
New York, New York
Conditions
Polycystic Kidney Disease
Interventions
Not listed
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2030
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Wegener's Granulomatosis, Microscopic Polyangiitis, Churg Strauss Syndrome, Polyarteritis Nodosa, Giant Cell Arteritis, Takayasu Arteritis
Interventions
Not listed
Lead sponsor
University of Oxford
Other
Eligibility
18 Years and older
Enrollment
3,588 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 11 more
Conditions
Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage IA Cutaneous Melanoma AJCC v8, Clinical Stage IB Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8, Clinical Stage IIA Cutaneous Melanoma AJCC v8, Clinical Stage IIB Cutaneous Melanoma AJCC v8, Clinical Stage IIC Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma
Interventions
Ipilimumab, Nivolumab, Pembrolizumab, Quadrivalent Inactivated Influenza Vaccine, Resection, Nivolumab + Relatlimab
Biological · Procedure
Lead sponsor
Carlo Contreras
Other
Eligibility
18 Years to 99 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Multiple Myeloma, AL Amyloidosis, Chronic Lymphocytic Leukemia
Interventions
A single "booster" dose of the Moderna mRNA COVID-19 vaccine
Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Detroit, Michigan
Conditions
Sleep, Pediatrics, Adenotonsillectomy
Interventions
Not listed
Lead sponsor
Baylor College of Medicine
Other
Eligibility
13 Years to 18 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Houston, Texas
Conditions
Chronic Sinusitis
Interventions
PROPEL Mini Sinus Implant., Sinus Surgery alone, Propel Nova Sinus Implant
Device · Procedure
Lead sponsor
Intersect ENT
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
10
States / cities
Sacramento, California • Torrance, California • Norwalk, Connecticut + 7 more
Conditions
Neoplasm
Interventions
Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 20 mg, Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 40 mg, Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 100 mg, Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 120 mg, Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 140 mg, HCC Child-Pugh A expansion cohort: Regorafenib 100 mg, HCC Child-Pugh B expansion cohort: Regorafenib 100 mg, NSCLC expansion cohort: Regorafenib 100 mg
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
5
States / cities
Los Angeles, California • Aurora, Colorado • Houston, Texas + 1 more
Conditions
Solid Tumors
Interventions
BMS-986504, Daraxonrasib, Nivolumab + Relatlimab FDC, Temozolomide, Pumitamig, Pemetrexed, Carboplatin, Nab-paclitaxel, Gemcitabine, Paclitaxel
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
16
States / cities
San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 10 more
Conditions
Metastatic Fallopian Tube Carcinoma, Metastatic Ovarian Carcinoma, Metastatic Primary Peritoneal Carcinoma, Ovarian Endometrioid Tumor, Ovarian High Grade Serous Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Primary Peritoneal Cancer AJCC v7
Interventions
Berzosertib, Carboplatin, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
14
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Aurora, Colorado + 11 more
Completed No phase listed Observational

Patient Satisfaction Scales

NCT03686735
Conditions
All Orthopedic Disorders, New or Follow-up Patients
Interventions
5 anchors and numbers, 5 anchors and no numbers, Visual analog scale with 3 anchors and numbers, Visual analog scale with 3 anchors and no numbers
Other
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 89 Years
Enrollment
256 participants
Timeline
2018 – 2019
U.S. locations
6
States / cities
Austin, Texas
Conditions
Breast Cancer
Interventions
Anastrozole, AZD0530 (saracatinib), Placebo
Drug
Lead sponsor
Joyce Marie Slingerland, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
2
States / cities
Palo Alto, California • Miami, Florida
Conditions
Chronic Myeloid Leukemia
Interventions
Not listed
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,494 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
143
States / cities
Muscle Shoals, Alabama • Phoenix, Arizona • Sedona, Arizona + 129 more